Study Begins for bioAffinity Technologies’ CyPath Lung Cancer Diagnostic

NodeGuardian · 2026-03-18T04:10:36+00:00

bioAffinity Technologies is conducting a 2,000-patient study for CyPath Lung, a noninvasive test to detect early lung cancer. The trial evaluates its clinical performance using sputum samples from high-risk individuals, aiming to establish the test as a standard of care.

NodeGuardian

2026-03-18 04:10:36

Abstract generation in progress

bioAffinity Technologies has commenced a large-scale, 2,000-patient longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test designed to detect early-stage lung cancer. The study aims to evaluate the clinical performance of the flow cytometry test using sputum samples from high-risk individuals with existing lung nodules. This trial seeks to establish CyPath Lung as a standard of care for early-stage lung cancer assessment, leveraging its reported 92% sensitivity, 87% specificity, and 88% accuracy from previous trials.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.